TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16405522

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy based on BNP levels
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: BNP cut-off level of 1.25 pmol L(‐1)
Number of subjects: 2213

Group type: COMPARATOR
Intervention: Control group (uneventful follow-up)
Number of subjects: 2213
Study: 15327820

Group type: EXPERIMENTAL
Intervention: High Tech VR
Number of subjects: 2

Group type: COMPARATOR
Intervention: Low Tech VR
Number of subjects: 2
Study: 11037672

Group type: EXPERIMENTAL
Intervention: Ambulatory rehabilitation programme for mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Utilisation of the health care system
Number of subjects: 0
Study: 9288223

Group type: COMPARATOR
Intervention: pcV
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: clindamycin
Number of subjects: 53
Study: 7680832

Group type: EXPERIMENTAL
Intervention: Synthetic porcine galanin (0.5 mg in 100 ml saline)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion (100 ml saline)
Number of subjects: 6
Study: 3554804

Group type: EXPERIMENTAL
Intervention: Bencyclane 200 mg b.i.d.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 29708822

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg TID for 2 weeks (open-label treatment)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg TID for 2 weeks (double-blind treatment)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo for 2 weeks (double-blind treatment)
Number of subjects: 103
Study: 27924635

Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 66

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 66
Study: 25887713

Group type: EXPERIMENTAL
Intervention: Complex nursing care intervention of CAM
Number of subjects: 590

Group type: COMPARATOR
Intervention: Usual nursing care (Control)
Number of subjects: 590
Study: 24167181

Group type: EXPERIMENTAL
Intervention: Exposure to monochlorophenoxy acid or ester herbicides
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Exposure to insecticides (aldicarb, dimethoate, phorate, petroleum oils)
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Exposure to adjuvant polyoxyethylene sorbitol
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Exposure to 2,6-dinitroaniline herbicides
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Exposure to herbicide oxyfluorfen
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Exposure to fungicide copper sulfate
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Exposure to chloroacetanilide herbicides
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Exposure to polyalkyloxy compounds used as adjuvants
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Exposure to insecticides (aldicarb, acephate)
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Exposure to adjuvant nonyl-phenoxy-poly(ethylene oxy)ethanol
Number of subjects: 2885
Study: 21418448

Group type: EXPERIMENTAL
Intervention: Community-based environmental management in intervention blocks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine vector control activities in control blocks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison of intervention vs control
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Affected intervention blocks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Community-based environmental management
Number of subjects: 59
Study: 19563205

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion treatment
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Routine medicine treatment
Number of subjects: 1076
Study: 17417987

Group type: EXPERIMENTAL
Intervention: Oxaceprol 1200 mg/day
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 15351584

Group type: EXPERIMENTAL
Intervention: Unilateral pudendal nerve blockade with 10 mg of 1% prilocaine (group 1, n = 26)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo control with 10 mL of 0.9 NaCl solution (group 2, n = 25)
Number of subjects: 51
Study: 11496278

Group type: EXPERIMENTAL
Intervention: High end-diastolic blood flow velocities
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low end-diastolic blood flow velocities
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Maximum systolic and end-diastolic blood flow velocities
Number of subjects: 45
Study: 9566835

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic and linoleic acid (1 g/day of each fatty acid) for 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oleic acid and linoleic acid for 6 weeks
Number of subjects: 15
Study: 7997384

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg alone
Number of subjects: 7

Group type: COMPARATOR
Intervention: Itraconazole 200 mg with concomitant ddI 300 mg
Number of subjects: 7
Study: 2454893

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster dose of vaccine at 15 months
Number of subjects: 0
Study: 31939911

Group type: EXPERIMENTAL
Intervention: Aerobic Plus Resistance Training (150 min of moderate intensity aerobic activity and 2 days of resistance training per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information only control group (monthly newsletters on type 2 diabetes education and prevention)
Number of subjects: 0
Study: 31343582

Group type: EXPERIMENTAL
Intervention: Motivational telephone intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Per-protocol analysis of motivational telephone intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Per-protocol analysis of standard of care (control)
Number of subjects: 100
Study: 28680370

Group type: EXPERIMENTAL
Intervention: PRO + AO
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PRO
Number of subjects: 60

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 60
Study: 25869875

Group type: EXPERIMENTAL
Intervention: Exercise training (90 min, twice a week for 12 weeks)
Number of subjects: 200
Study: 23391488

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 35
Study: 21212064

Group type: EXPERIMENTAL
Intervention: CD‐ROM aid
Number of subjects: 239

Group type: COMPARATOR
Intervention: Brief description of the test (Control)
Number of subjects: 239
Study: 18788531

Group type: EXPERIMENTAL
Intervention: Beijing Hypertensive No. 0
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Other antihypertensive drugs (Control)
Number of subjects: 4000
Study: 15893416

Group type: EXPERIMENTAL
Intervention: Imatinib (2x400 mg po daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m2 weekly)
Number of subjects: 26
Study: 12610034

Group type: EXPERIMENTAL
Intervention: Clinical model
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: 2-h glucose
Number of subjects: 465

Group type: COMPARATOR
Intervention: FPG
Number of subjects: 465
Study: 11063900

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 2016
Study: 9359745

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (zidovudine, didanosine, nevirapine)
Number of subjects: 15
Study: 8229656

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) treatment group
Number of subjects: 0
Study: 6495086

Group type: EXPERIMENTAL
Intervention: Gastric aspiration in erect position
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gastric aspiration in supine position
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 12-hour gastric aspirates
Number of subjects: 15

Group type: COMPARATOR
Intervention: Posture change (erect vs supine)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gallbladder contraction stimulated by intravenous pancreozymin
Number of subjects: 15
Study: 31300280

Group type: EXPERIMENTAL
Intervention: Advax-adjuvanted honeybee venom immunotherapy (HBVIT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Honeybee venom immunotherapy (VIT) without Advax adjuvant
Number of subjects: 27
Study: 28940207

Group type: EXPERIMENTAL
Intervention: Affective primes with three levels of working-memory load during prime processing.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High cognitive load during prime processing.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low stimulus value indicated by medial-frontal negativity.
Number of subjects: 47
Study: 27287343

Group type: EXPERIMENTAL
Intervention: Active PEMF treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Inactive PEMF (placebo)
Number of subjects: 8
Study: 24964759

Group type: EXPERIMENTAL
Intervention: Intravenous CCRT (n = 80)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Intraarterial CCRT (n = 78)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 158
Study: 20843245

Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate (178 patients)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo (162 patients)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate and Placebo
Number of subjects: 340
Study: 15486066

Group type: EXPERIMENTAL
Intervention: MTX-4h (methotrexate as intravenous infusion over 4 hours)
Number of subjects: 505

Group type: COMPARATOR
Intervention: MTX-24h (methotrexate as intravenous infusion over 24 hours)
Number of subjects: 505

Group type: COMPARATOR
Intervention: MTX 1 g/m(2) (in NHL-BFM95)
Number of subjects: 505

Group type: COMPARATOR
Intervention: MTX 5 g/m(2) (in NHL-BFM90)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: MTX-4h
Number of subjects: 505
Study: 11443161

Group type: EXPERIMENTAL
Intervention: Antithyroid drug pretreatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 42
Study: 9537629

Group type: EXPERIMENTAL
Intervention: Providing breakfast to students at school
Number of subjects: 2

Group type: COMPARATOR
Intervention: Better-organized schools
Number of subjects: 2

Group type: COMPARATOR
Intervention: Poorly organized schools
Number of subjects: 2
Study: 7517239

Group type: EXPERIMENTAL
Intervention: HES 200/0.5 10%
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.9% NaCl solution
Number of subjects: 100
Study: 2511910

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg three times daily
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1127088

Group type: EXPERIMENTAL
Intervention: 15 mg calcium/kg (calcium gluconate at 3 ml/min for 3 h followed by normal saline for the fourth hour)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal saline at 3 ml/min for 4 h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: l-dopa (500 mg oral dose) during normal saline and calcium infusions
Number of subjects: 9
Study: 31732868

Group type: EXPERIMENTAL
Intervention: Main meal dominant pattern (3 main eating occasions + 0-3 snacks)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Snack dominant pattern (3 main eating occasions + >3 snacks)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Large meal dominant pattern (≤2 main eating occasions + <2 snacks)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Main meal dominant pattern
Number of subjects: 143
Study: 28816033

Group type: EXPERIMENTAL
Intervention: 2000 mg bilayer sustained-release acetaminophen (APAP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 1000 mg immediate-release acetaminophen (APAP) taken 6 hours apart
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2000 mg single-layer sustained-release acetaminophen (APAP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2000 mg single-layer sustained-release acetaminophen (APAP) with different excipient
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2000 mg enteric-coated sustained-release acetaminophen (APAP) with fast-dissolving IR APAP
Number of subjects: 14
Study: 27481125

Group type: EXPERIMENTAL
Intervention: Misoprostol (400μg vaginally, 12h before procedure)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Bladder distension (1 litre of water, 2h before procedure)
Number of subjects: 76
Study: 24114402

Group type: EXPERIMENTAL
Intervention: High-dose intervention (HI) group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 44
Study: 23176993

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5% administered over 1 min (fast) in Group F
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5% administered over 3 min (slow) in Group S
Number of subjects: 60
Study: 20571979

Group type: EXPERIMENTAL
Intervention: LY-2140023
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18691986

Group type: EXPERIMENTAL
Intervention: Test formulation of ketotifen fumarate ophthalmic solution 0.025%
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Reference formulation of ketotifen fumarate ophthalmic solution 0.025%
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (inactive vehicle)
Number of subjects: 108
Study: 16279896

Group type: EXPERIMENTAL
Intervention: Hepatobiliary randomized clinical trials
Number of subjects: 530
Study: 16583968

Group type: EXPERIMENTAL
Intervention: Voluntary surgical contraception (VSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vasectomy (control group)
Number of subjects: 0
Study: 10461002

Group type: EXPERIMENTAL
Intervention: Laminaria tent insertion followed by ethacridine lactate (Rivanol) instillation (n = 34)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nelathon catheter-condom method (n = 50)
Number of subjects: 91
Study: 8923016

Group type: EXPERIMENTAL
Intervention: Chemopreventive agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 1800929

Group type: EXPERIMENTAL
Intervention: Topical 2% cyclosporine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6625962

Group type: EXPERIMENTAL
Intervention: Active dialysis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study: 31662969

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 14
Study: 30075806

Group type: EXPERIMENTAL
Intervention: Brief CETA (5 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard CETA (8-12 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief CETA and Standard CETA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 26786589

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 48
Study: 24368753

Group type: EXPERIMENTAL
Intervention: QRS duration ≥ 120 ms
Number of subjects: 3804

Group type: EXPERIMENTAL
Intervention: QRS duration 90-119 ms
Number of subjects: 3804

Group type: EXPERIMENTAL
Intervention: QRS duration ≥ 120 ms with heart failure (HF)
Number of subjects: 3804

Group type: EXPERIMENTAL
Intervention: QRS duration ≥ 120 ms without heart failure (HF)
Number of subjects: 3804

Group type: EXPERIMENTAL
Intervention: QRS duration 90-119 ms with heart failure (HF)
Number of subjects: 3804

Group type: EXPERIMENTAL
Intervention: QRS duration 90-119 ms without heart failure (HF)
Number of subjects: 3804
Study: 22315155

Group type: EXPERIMENTAL
Intervention: leuprolide 3.75 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: leuprolide 7.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: goserelin 3.6 mg
Number of subjects: 60
Study: 20018365

Group type: EXPERIMENTAL
Intervention: 7.5 microg, 15 microg, or 30 microg haemagglutinin vaccine
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1173
Study: 17394665

Group type: EXPERIMENTAL
Intervention: 90 minutes of moderate intensity exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 8
Study: 15809123

Group type: EXPERIMENTAL
Intervention: Racemic bupivacaine (2.5 mg) + fentanyl (25 microg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: L-bupivacaine (2.5 mg) + fentanyl (25 microg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Racemic bupivacaine and L-bupivacaine
Number of subjects: 67
Study: 12114402

Group type: EXPERIMENTAL
Intervention: CTP37-DT vaccine administered intramuscularly on days 0, 28, and 70.
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 77
Study: 10665017

Group type: EXPERIMENTAL
Intervention: Personal goals
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Difficult assigned goals
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Easy assigned goals
Number of subjects: 40

Group type: COMPARATOR
Intervention: No goals
Number of subjects: 40
Study: 7553242

Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray with benzalkonium chloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxymetazoline nasal spray alone
Number of subjects: 20
Study: 2081899

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 274263

Group type: EXPERIMENTAL
Intervention: 0.2% SnF2 solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3% SnF2 solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 30989175

Group type: EXPERIMENTAL
Intervention: Oral antibiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged intravenous therapy
Number of subjects: 0
Study: 29336753

Group type: EXPERIMENTAL
Intervention: Lightweight mesh
Number of subjects: 67

Group type: COMPARATOR
Intervention: Heavyweight mesh
Number of subjects: 67
Study: 25536008

Group type: EXPERIMENTAL
Intervention: Beetroot juice (140 mL, providing 12.9 mmol of nitrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted Beet-It Sport)
Number of subjects: 12
Study: 23827657

Group type: EXPERIMENTAL
Intervention: Behavioural Activation for Worry (BAW)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 49
Study: 21980205

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: Stroke events
Number of subjects: 2502
Study: 19788968

Group type: EXPERIMENTAL
Intervention: Duration of active second-stage labor (1 hour)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Duration of active second-stage labor (2 hours)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Duration of active second-stage labor (>3 hours)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Duration of pushing (after 2 hours)
Number of subjects: 1862
Study: 16448575

Group type: EXPERIMENTAL
Intervention: Primaquine (PQ) 45 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bulaquine (BQ) 75 mg
Number of subjects: 90
Study: 15561834

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate exposure during the previous 3 months
Number of subjects: 648
Study: 11783028

Group type: EXPERIMENTAL
Intervention: CCNU or BCNU after 20-40 Gy irradiation to the brain
Number of subjects: 56

Group type: COMPARATOR
Intervention: Radiation treatment alone
Number of subjects: 56
Study: 9778203

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate (5 mg/d)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Nifedipine coat core (30 mg/d)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (GITS) (30 mg/d)
Number of subjects: 192

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 192
Study: 7937860

Group type: EXPERIMENTAL
Intervention: Laser-induced fluorescence at 337-nm excitation
Number of subjects: 28
Study: 2455114

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Reactive hyperemia after arterial occlusion combined with handgrip exercise and local heating
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Arterial occlusion combined with nifedipine
Number of subjects: 22
Study: 31077519

Group type: EXPERIMENTAL
Intervention: Individualized Occupational Therapy (IOT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Group Occupational Therapy (GOT) alone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: GOT + IOT
Number of subjects: 111

Group type: COMPARATOR
Intervention: GOT-alone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Type of occupational therapy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Access to resident support persons
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Executive function at discharge
Number of subjects: 111
Study: 30120445

Group type: EXPERIMENTAL
Intervention: Transitive syntactic frames
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intransitive syntactic frames
Number of subjects: 32
Study: 27535371

Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (inert lotion)
Number of subjects: 24
Study: 24777691

Group type: EXPERIMENTAL
Intervention: Colesevelam 1.5-4.5 g/day
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 22798322

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids with vitamin D deficiency
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids with vitamin D insufficiency
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids with vitamin D sufficiency
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Inhaled corticosteroids (control group)
Number of subjects: 1024